Oxford, MS 8/1/2011 (PennyPayDay) -- Amarantus BioSciences, Inc. (OTC:AMBS), a biotechnology company developing MANF, a first-in-class, disease-modifying therapeutic protein that addresses an underlying form of cell death known as apoptosis, announced recently, in a press release, positive results from a pre-clinical experiment demonstrating that MANF significantly reduces the behavioral deficits caused by the neurotoxin 6-OHDA in a standard animal model of Parkinson's disease. AMBS is also under an e-mail marketing campaign initiated by a third party investor this morning. As I write, shares of AMBS were up 23 percent at $0.37 per share on heavy volume of more than 922,000 shares.The experiments were funded by a research grant from the Michael J. Fox Foundation for Parkinson's Research and presented at a meeting of the Company's Scientific Advisory Board ("SAB") on April 29, 2011, confirming data previously reported in The Journal of Neuroscience on July 29, 2009.
"We are very encouraged by the data set presented at the April SAB meeting," said Martin D. Cleary, Chairman and Chief Executive Officer of Amarantus. "Parkinson's disease is the centerpiece of Amarantus' internal CNS development effort and meeting this critical milestone internally validates the published literature which describes MANF's broad anti-apoptosis potential, while adding value to the extensive MANF intellectual property portfolio the Company owns and is actively prosecuting to treat CNS and other disease categories. We will now focus our CNS efforts on the advancement of the MANF product development program for Parkinson's disease by executing the protocols required to gain Investigational New Drug status with the FDA."
Amarantus BioSciences, Inc. is engaged in the research and development of first-in-class disease-modifying treatments that address the underlying cause of cell death, known as apoptosis, associated with a wide range of diseases. The Company's most advanced product candidate, MANF, is a therapeutic protein indicated for the treatment of Parkinson's disease and Myocardial Infarction. Currently incubating at the Parkinson's Institute in Sunnyvale, CA, Amarantus BioSciences is the recipient of a research grant from The Michael J. Fox Foundation for Parkinson's Research.
PennyPayday Free Stock Quotes and Approach to the Stock Market
PennyPayday focuses on bringing penny stocks and small-cap companies, such as (AMBS) from all exchanges into the spotlight for investors seeking early development opportunities. PennyPayday has quickly become a recognized penny stock site and a top source for investors seeking information and research on today's emerging hot stocks. PennyPayday provides the investing public with stock market daily news, free real-time stock quotes, free stock charts, research for investing, as well as economic stories, videos, and market briefs from a staff of experienced and dedicated financial journalists.
Sign up for our Free Newsletter today, and join the thousands already getting our emails on the hottest stocks to watch.
Disclaimer: Neither www.PennyPayday.com nor its officers, directors, partners, employees or anyone involved in the publication of this website or newsletters is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. PennyPayday may or may not have been compensated by mentioned companies: (AMBS). For full disclaimer/disclosure please read PennyPayday's disclaimer.
No comments:
Post a Comment